Clinical Trial Detail

NCT ID NCT02767934
Title Pembrolizumab in Treating Minimal Residual Disease in Patients With Acute Lymphoblastic Leukemia
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements No
Sponsors University of Washington
Indications

acute lymphoblastic leukemia

Therapies

Pembrolizumab

Age Groups: adult

No variant requirements are available.